Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04339036 · ClinicalTrials.gov registry record · Phase 2
CapTemY90 for Grade 2/3 NET Liver Metastases
A Phase 2 study of Neuroendocrine Tumors and Neuroendocrine Tumor Grade 2, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 4
- Study locations
NCT04339036: Recruiting Phase 2 study of Neuroendocrine Tumors and Neuroendocrine Tumor Grade 2, sponsored by Abramson Cancer Center at Penn Medicine.
NCT04339036 is a Phase 2 study of Neuroendocrine Tumors and Neuroendocrine Tumor Grade 2 that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 70 participants, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (61% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04339036, a Phase 2 study of Neuroendocrine Tumors and Neuroendocrine Tumor Grade 2, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone. A Grade 3 arm was added in 2025.
Primary Outcome
Intra-hepatic progression-free survival by RECIST 1.0 is defined as the time from initiation of study therapy until first documented intra-hepatic disease progression, death due to any cause or last scan date that documented intra-hepatic progression-free status.
Conditions Studied
Interventions
- DRUG Capecitabine Oral Product
- DRUG Temozolomide Oral Product
- COMBINATION_PRODUCT transarterial radioembolization
Study Locations (4)
California
- UC San Diego - La Jolla
Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-10-07 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 2 |
What NCT04339036 shows while recruiting
NCT04339036 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (61% lower).
The record links to 2 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 3 interventions - of which Capecitabine Oral Product is the first listed.
NCT04339036 reports a single indexed study location in California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT04339036 about?
NCT04339036 is a clinical study titled "CapTemY90 for Grade 2/3 NET Liver Metastases". This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation fr...
What is the current status of trial NCT04339036?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2021-10-07. Estimated completion is 2026-05-01.
What conditions does trial NCT04339036 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Neuroendocrine Tumor Grade 2.
What interventions are being tested in trial NCT04339036?
The interventions under investigation include: Capecitabine Oral Product (DRUG), Temozolomide Oral Product (DRUG), transarterial radioembolization (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04339036?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04339036 being conducted?
This trial has 4 study locations across California, Florida, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04339036's enrollment target sits among peer trials
70 24th of 52 higher than 28 of 52 other Neuroendocrine Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroendocrine Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI